» Articles » PMID: 7862855

Cross-tolerance Studies of Serotonin Receptors Involved in Behavioral Effects of LSD in Rats

Overview
Specialty Pharmacology
Date 1994 Jan 1
PMID 7862855
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Like hallucinogenic 5-HT2 agonists, LSD (d-lysergic acid diethylamide) produces characteristic decreases in locomotor activity and investigatory behaviors of rats tested in a novel environment. Because LSD is an agonist at both 5-HT1A and 5-HT2 receptors, however, the respective influences of these different receptors in the behavioral effects of LSD remain unclear. In particular, the paucity of selective 5-HT1A antagonists has made it difficult to assess the specific contribution of 5-HT1A receptors to the effects of LSD. An alternative approach to the delineation of receptor-specific effects is the use of cross-tolerance regimens. In the present studies, rats were pretreated with saline, 8-hydroxy-2(di-n-propylamino)-tetralin (8-OH-DPAT) (0.5 mg/kg SC), 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (1.0 mg/kg SC), or LSD (60 micrograms/kg SC), every 12 h for 5 or 8 days. Thirty-six hours later, rats were tested in a behavioral pattern monitor 10 min after injection of saline, 0.5 mg/kg 8-OH-DPAT, 1.0 mg/kg DOI, or 60 micrograms/kg LSD. As expected, tolerance to the decreases in locomotor activity produced by acute administrations of 8-OH-DPAT, DOI, or LSD occurred when rats were pretreated chronically with 8-OH-DPAT, DOI, or LSD, respectively. Furthermore, pretreatment with either 8-OH-DPAT or DOI produced cross-tolerance to LSD. These results support the hypothesis that the effects of LSD in this model reflect a combination of 5-HT1A and 5-HT2 effects and support the view that there is an interaction between 5-HT1A and 5-HT2 receptors.

Citing Articles

1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review.

Glennon R, Dukat M ACS Pharmacol Transl Sci. 2024; 7(6):1722-1745.

PMID: 38898956 PMC: 11184610. DOI: 10.1021/acsptsci.4c00157.


Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence.

Inserra A, Piot A, De Gregorio D, Gobbi G CNS Drugs. 2023; 37(9):733-754.

PMID: 37603260 DOI: 10.1007/s40263-023-01008-5.


Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission.

De Gregorio D, Popic J, Enns J, Inserra A, Skalecka A, Markopoulos A Proc Natl Acad Sci U S A. 2021; 118(5).

PMID: 33495318 PMC: 7865169. DOI: 10.1073/pnas.2020705118.


Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use.

Sherwood A, Claveau R, Lancelotta R, Kaylo K, Lenoch K ACS Omega. 2020; 5(49):32067-32075.

PMID: 33344861 PMC: 7745443. DOI: 10.1021/acsomega.0c05099.


Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics.

Schindler E, Wallace R, Sloshower J, DSouza D Front Pharmacol. 2018; 9:177.

PMID: 29545753 PMC: 5838010. DOI: 10.3389/fphar.2018.00177.


References
1.
Glennon R, Titeler M, McKenney J . Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984; 35(25):2505-11. DOI: 10.1016/0024-3205(84)90436-3. View

2.
Arnt J, Hyttel J . Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol. 1989; 161(1):45-51. DOI: 10.1016/0014-2999(89)90178-7. View

3.
Hamon M, Lanfumey L, El Mestikawy S, Boni C, Miquel M, Bolanos F . The main features of central 5-HT1 receptors. Neuropsychopharmacology. 1990; 3(5-6):349-60. View

4.
BELLEVILLE R, FRASER H, ISBELL H, LOGAN C, Wikler A . Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. AMA Arch Neurol Psychiatry. 1956; 76(5):468-78. View

5.
Berendsen H, Broekkamp C . Attenuation of 5-HT1A and 5-HT2 but not 5-HT1C receptor mediated behaviour in rats following chronic treatment with 5-HT receptor agonists, antagonists or anti-depressants. Psychopharmacology (Berl). 1991; 105(2):219-24. DOI: 10.1007/BF02244313. View